Silence Therapeutics (ADR) (SLN)
Develops liver-targeted siRNA medicines through its mRNAi GOLD platform.
Something off on this page? Send us feedback.
Develops liver-targeted siRNA medicines through its mRNAi GOLD platform. As a clinical-stage biotechnology company, it advances programs for polycythemia vera, high lipoprotein(a), and dyslipidemia while using external collaboration in discovery.
Develops siRNA medicines through the mRNAi GOLD platform, which uses RNA interference to target disease-associated genes without permanently altering DNA. Its GalNAc linkage is designed to direct siRNAs to liver cells, making liver-targeted discovery the core of its operating model. It also supports liver-focused partnered discovery with external collaborators.
The clinical pipeline includes divesiran for polycythemia vera, zerlasiran for high lipoprotein(a), and SLN312 for dyslipidemia. The company also uses external collaboration in discovery and alliance management. Its Nasdaq-listed ADSs are its only publicly tradable securities after the AIM admission was cancelled.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 24, 2026 | Cantor Fitzgerald | Initiate | Rating: — |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $72.1M · Total debt $112.0K · Total assets $106.4M · Shareholders' equity $38.5M
- Revenue
- $0
- Operating income
- −$13.1M
- Net income
- −$12.3M
No dividends on record.
| Institutions | 47.07% | 22.24M ADS | |
|---|---|---|---|
| 76 holders · as of Jun 30, 2026 | |||
| Insiders | 40.09% | 18.94M ADS | |
| 8 holders · as of Aug 13, 2026 | |||
| Other | 12.84% | 6.07M ADS | |
| remainder | |||
47.25M ADS (1 ADS = 3 ordinary shares) as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Richard Ian Griffiths1Insider10 percent owner | 40.00% | 34.54M ordinary | filed Aug 13, 2026 |
Siren, L.L.C.Institution | 7.01% | 3.31M ADS | as of Jun 30, 2026 |
TCG Crossover Management, LLCInstitution | 6.42% | 3.03M ADS | as of Jun 30, 2026 |
Redmile Group, LLCInstitution | 4.58% | 2.16M ADS | as of Jun 30, 2026 |
Nantahala Capital Management, LLCInstitution | 2.85% | 1.35M ADS | as of Jun 30, 2026 |
- Richard Ian Griffiths's own ownership statement (13D, Jun 25, 2025) plus the 7.38M net shares acquired since reports fewer shares than the transaction reports; the statement is used.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 10, 2026 | Richard Ian Griffiths | 10 percent owner | −5,484,320 | $16.00 |
| Jul 6, 2026 | Richard Ian Griffiths | 10 percent owner | −865,112 | $10.53 |
| Jul 2, 2026 | Richard Ian Griffiths | 10 percent owner | −50,082 | $10.47 |
| Jul 1, 2026 | Richard Ian Griffiths | 10 percent owner | −129,180 | $10.62 |
| Jun 30, 2026 | Richard Ian Griffiths | 10 percent owner | −169,928 | $10.76 |
- Amgen
Late-stage siRNA competitor in high Lp(a)
- Novartis (ADR)
Phase 3 antisense competitor in high Lp(a)
- Eli Lilly
siRNA competitor in high Lp(a) lowering
- Protagonist Therapeutics
Late-stage PV competitor targeting hematocrit control
- Arrowhead Pharmaceuticals
RNAi competitor in ANGPTL3-linked dyslipidemia
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Silence Therapeutics (ADR) | $12.37 | +0.98% | $578.6M | — | — | 941.9 | −38.8% |
| Amgen | $409.88 | +4.25% | $212.19B | 24.4 | 17.5 | 5.6 | +9.7% |
| Novartis (ADR) | $141.56 | +0.41% | $267.96B | 21.3 | 15.1 | 4.8 | +0.9% |
| Eli Lilly | $1,171.76 | +0.59% | $1.10T | 39.1 | 28.7 | 13.8 | +47.7% |
| Protagonist Therapeutics | $145.45 | +0.33% | $9.32B | 140.3 | 72.6 | 33.1 | +3,749.2% |
| Arrowhead Pharmaceuticals | $71.94 | +4.57% | $9.69B | — | — | 14.5 | +171.0% |
| Median | 31.8 | 23.1 | 13.8 | +47.7% |